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Resumo 
Introdução: O ouvido interno é o órgão sensorial responsável pela manutenção do equilíbrio e pela 
capacidade auditiva. A surdez é a deficiência neuro-sensorial mais comum no Ser Humano, podendo ter 
uma origem genética e/ou ambiental. A presbiacusia, ou surdez associada à idade, é um tipo de surdez 
neuro-sensorial progressivo e bilateral, que resulta do efeito cumulativo de fatores intrínsecos e 
extrínsecos, levando à degeneração da cóclea e das vias centrais auditivas. Estudos prévios indicam uma 
predisposição genética para o desenvolvimento de presbiacusia. A surdez neuro-sensorial pode ocorrer 
associada a outros sintomas e ser intermitente em algumas manifestações como na doença de Meniere. 
A doença de Meniere é uma doença multifatorial, caraterizada por ataques de vertigens espontâneos, 
associado a surdez neuro-sensorial unilateral intermitente, acufenos e uma sensação de preenchimento 
do ouvido (“aura”). Os pacientes com doença de Meniere podem também desenvolver surdez neuro-
sensorial bilateral, enxaquecas e doenças autoimunes sistémicas. Apesar da doença de Meniere ser 
considerada multifatorial, existem três hipóteses mais aceites para a sua etiologia - genética, autoimune 
ou alérgica – existindo evidências científicas para todas elas. A prevalência de alergias diagnosticadas 
em pacientes de doença de Meniere é três vezes superior à população geral. Nas doenças do ouvido há 
também a considerar as doenças vestibulares, que levam à perda transiente ou permanente da função 
vestibular. A Enxaqueca Vestibular é caraterizada pela ocorrência de episódios de sintomas vestibulares 
e uma história de enxaqueca, com uma associação temporal em pelo menos 50% dos ataques. A 
Enxaqueca Vestibular é mais comum em pacientes com doença de Meniere do que na população geral, 
podendo por vezes serem indistinguíveis baseado apenas em historial médico e sintomas, podendo 
também apresentar-se como uma comorbidade. Porém, a relação patofisiológica entre Enxaqueca 
Vestibular e doença de Meniere é desconhecida.  
Objetivos: Caracterização genética de pacientes de presbiacusia a nível dos genes GRM7 e NAT2 e 
haplogrupos de mtDNA; comparação da resposta imune induzida por fungos entre pacientes de doença 
de Meniere e Enxaqueca Vestibular. 
Materiais e Métodos: Estudo e análise das caraterísticas demográficas e clinicas dos indivíduos da 
amostra de presbiacusia (n=483, oriunda da população portuguesa), doença de Meniere (n=115, oriundas 
da população espanhola) e Enxaqueca Vestibular (n=73, oriundas da população espanhola); 
sequenciação da região HVS1 do DNA mitocondrial e determinação de haplogrupos utilizando o 
mtDNA Haplogroup Analysis software; genotipagem por real-time PCR dos genes GRM7 (rs11928865) 
e NAT2 (rs1799930, rs1799931, rs1801280, rs1208, rs1041983, rs1799929 e rs1801279). Determinação 
do fenótipo de acetilação do gene NAT2 utilizando NAT2PRED software. Determinação do nível de 
expressão de citocinas (IL-1β, IL-1RN, IL-6 e TNFα) em amostras de indivíduos com Enxaqueca 
Vestibular por PCR quantitativo e quantificação do nível de liberação extracelular das mesmas 
utilizando um Multiplex Bead-Based Kit; determinação da expressão génica por microarray de 
Enxaqueca Vestibular e Doença de Meniere; determinação das vias canónicas, identificação de 
reguladores e predição do estado (ativo/inibido) utilizando IPA® software. 
Resultados e Discussão: Os nossos resultados demonstram que na amostra de pacientes com 
presbiacusia há diferenças significativas entre a idade e o nível de perda auditiva, os homens têm uma 
melhor audição nas baixas frequências e as mulheres nas altas frequências evidenciando um efeito de 
inversão. Distintas comorbidades foram associadas a presbiacusia, nomeadamente: níveis de colesterol 
elevado, hipertensão, doença cardiovascular e hábitos tabágicos. O genótipo T/T do SNP rs11928865 
do gene GRM7 confere uma maior perda auditiva a 8000 Hz. O haplótipo NAT2*4/NAT2*6A está 
associado a uma maior perda auditiva a 250 Hz. O fenótipo de acetilação lenta, no gene NAT2, tem uma 
maior perda auditiva, porém não existem diferenças significativas entre este fenótipo e os restantes. A 
origem dos haplogrupos mais detetados na nossa amostra é europeia, sendo o haplogrupo mais comum 
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o haplogrupo H, porém também foram identificados haplogrupos asiáticos e um haplogrupo africano. 
Apesar de não terem sido encontradas diferenças significativas, o haplogrupo com maior perda auditiva 
é o haplogrupo X. Os resultados de qPCR revelam que os pacientes com Enxaqueca Vestibular 
comparativamente a controlos saudáveis, quando estimulados com Aspergillus têm uma maior 
expressão de IL-1, TNFα e IL-6, porém apenas a diferença em IL-6 é estatisticamente significativa. No 
entanto, não se vê uma diferença na expressão de citocinas após estimulação com Penicillium. Os níveis 
basais de IL-1RA são mais elevados em Enxaqueca Vestibular do que nos controlos. Os níveis de IL-6 
e TNFα são mais elevados em Enxaqueca Vestibular do que em controlos após estimulação com 
Aspergillus e Penicillium. Não existem diferenças significativas entre os níveis basais de Enxaqueca 
Vestibular e doença de Meniere com baixos níveis de IL-1β, porém existem diferenças significativas 
entre os níveis de IL-1RA de Enxaqueca Vestibular e doença de Meniere com baixos níveis de TNFα e 
entre os níveis de IL-1β, IL-1RA, IL-6 e TNFα de EV e doença de Meniere com elevados níveis de IL-
1β e TNFα. Após estimulação, verifica-se uma diferença nos níveis de IL-1RA e IL-6 entre Enxaqueca 
Vestibular e doença de Meniere com baixos níveis de IL-1β e TNFα e uma diferença entre os níveis de 
IL-1RA entre Enxaqueca Vestibular e doença de Meniere com elevados níveis de IL-1β e TNFα. Não 
existem diferenças significativas entre os perfis de expressão génica entre pacientes de Enxaqueca 
Vestibular e controlos saudáveis e entre pacientes de Enxaqueca Vestibular e pacientes de doença de 
Meniere com baixos níveis de citocinas. Porém, existem diferenças entre pacientes com Enxaqueca 
Vestibular e pacientes com Doença de Meniere com elevados níveis de citocinas, que revelam o 
envolvimento da maturação de linfócitos B, produção de citocinas e a maturação de células dendríticas. 
A comparação da resposta a Aspergillus e Penicillium entre pacientes com Enxaqueca Vestibular e 
controlos saudáveis revelou diferenças no envolvimento da produção de citocinas, inflamação e da 
sinalização para a morte celular programada. A comparação da resposta a estimulação com Aspergillus 
e Penicillium entre pacientes com Enxaqueca Vestibular e Doença de Meniere revelou o envolvimento 
de reguladores que atuam na diferenciação, ativação e regulação de linfócitos T, no desenvolvimento de 
linfócitos B, na maturação de células dendríticas e na alergia.  
Conclusão: As doenças do ouvido interno podem ter várias causas e comorbidades associadas. Na nossa 
amostra de presbiacusia, os haplogrupos de mtDNA não mostram qualquer efeito na perda auditiva. Não 
se pode excluir o efeito genético de GRM7, NAT2 e haplogrupos do mtDNA na presbiacusia, no entanto 
na nossa amostra os fatores ambientais poderão ter um maior efeito para o desenvolvimento de 
presbiacusia do que os fatores genéticos analisados, ainda que seja de considerar o possível efeito de 
outros fatores genéticos nomeadamente os associados às alterações do colesterol. Os pacientes de 
Enxaqueca Vestibular podem ser distinguidos de controlos saudáveis e de pacientes de Doença de 
Meniere a partir dos níveis basais de IL-1RA. Os resultados do microarray suportam os resultados 
obtidos através na quantificação dos níveis extracelulares de IL-1β, IL-1RA, IL-6 e TNFα e sugerem 
uma resposta alérgica nos pacientes de Enxaqueca Vestibular. 
 
Palavras-chave: Ouvido interno; Presbiacusia; Doença de Meniere; Enxaqueca Vestibular 
  
 viii 
 
Abstract 
Introduction: The inner ear is a sensory organ responsible for the maintenance of balance and 
equilibrium and hearing. Age-related hearing loss (ARHL) results from the cumulative effect of intrinsic 
and extrinsic factors that lead to degenerative changes related to ageing of the cochlea and central 
auditory pathways. Meniere’s Disease (MD) is a multifactorial disorder characterized by vertigo attacks 
usually associated to unilateral sensorineural hearing loss (SNHL), tinnitus and aural fullness. MD 
patients have higher prevalence of diagnosed allergy than the general population. Vestibular Migraine 
(VM) is defined by occurrence of episodic vestibular symptoms and a history of migraine, however it 
has high symptom overlapping with other vestibular disorders, such as MD.  
Objectives: Genetically characterize ARHL patients at GRM7, NAT2 and mtDNA haplogroups and 
compare the mold-induced immune response in VM and MD patients. 
Materials and Methods: Demographic and clinical characterization of ARHL, VM and MD cohorts. 
HVS1 region sequencing and mtDNA haplogroup determination; NAT2 and GRM7 analysis by Real 
time PCR; cytokine expression level determination by qPCR and extracellular cytokine quantification 
with Multiplex Bead-Based Kit and gene expression determining by microarray. 
Results: Cholesterol, hypertension, smoking and cardiovascular disease were identified as ARHL 
comorbidities. GRM7 genotypes have significant differences for hearing loss (HL) at 8000 Hz. 
NAT2*4/NAT2*6A is associated to worst listening at 250 Hz. The haplogroups identified in our sample 
are mostly European. Haplogroup X has highest HL (not statistically significant). Allergenic extracts 
induce a proinflammatory immune response involving TNF-α and IL-6. Stimulation leads to the 
involvement of upstream regulators that take part in differentiation, activation and regulation of T-cells, 
B-cell development, dendritic cell maturation and allergy. 
Conclusion: Other variables may prevail over the genetic factor in the Portuguese population of ARHL. 
Basal levels of IL1-RA may allow the distinction of VM and MD. The microarray data is supportive of 
the findings in the extracellular cytokine measurements and suggests an allergic response in VM. 
 
Key-words: Inner ear; Age-related Hearing Loss, Meniere’s Disease; Vestibular Migraine 
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1. Introduction 
 
1.1. The Inner Ear 
The inner ear is a sensory organ that consists of an osseous labyrinth of spaces in the temporal bone. 
Within it there is a fluid-filled membranous labyrinth, connected to the osseous labyrinth in various 
places. The endolymph fills the membranous labyrinth and the perilymph surrounds the 
perimembranous space. The perimembranous space is directly connected with the subarachnoid space, 
therefore the perilymph has a similar composition to cerebrospinal fluid, with low [K+] and high [Na+]. 
Oppositely, the membranous labyrinth is a closed system within the endolymphatic sac filled with 
endolymph, which has high [K+] and low [Na+] 1,2. 
The endolymphatic sac (ES) (figure 1.1) is part of the membranous labyrinth and it is believed to 
have a role in fluid and ion transport, maintaining the homeostasis of the endolymph and perilymph 
within the inner ear, however there is no conclusive data 3.  
The osseous labyrinth is composed by 
the vestibule, the semicircular canals and 
the cochlea (figure 1). The vestibule 
contains the utricle and the saccule, two 
components of the membranous 
labyrinth, which are connected by the 
endolymphatic duct. The macula is a 
specialised area of the sensory receptor 
cells, located at the walls of the utricle 
and the saccule, from which axons pass 
into the vestibular nerve as part of sensory 
inputs to maintain equilibrium. 1. 
The semicircular canals contain 
sensory receptors with axons converging on the vestibular nerve. Alongside with the macula, these 
receptors help maintain balance and equilibrium 1,2. 
The cochlea is a conical helix in the temporal bone, its lumen is continuous with that of the vestibule. 
The membranous canal of the cochlea arises from the saccule and spirals towards the apex of the osseous 
space and can be divided into three compartments. The scala media (middle compartment) contains 
endolymph and the scala vestibuli (upper compartment) and scala tympani (lower compartment) contain 
perilymph. The sound sensory receptors are located at the Organ of Corti 1,2.  
The organ of Corti, which lies in the scala media and rests on the basilar membrane, is a sensory 
epithelium structure containing receptor cells that allow hearing to happen. The organ of Corti vibrates 
in response to fluid movements and propagates this mechanical energy to the entire structure. Sound 
provokes a general wave within the cochlea, however the basilar membrane has different restricted 
response movements according to the sound frequency, as it is thinner at the base and thicker at the 
apex. The highest frequencies are sensed towards the base of the cochlea and gradually lower 
frequencies are sensed along the spiral towards the apex. For each frequency a specific point of the 
basilar membrane and organ of Corti vibrate and activate the appropriate hair cells to initiate afferent 
sensory impulses and consequentially send it to the auditory cortex of the brain. This frequency-specific 
property of the organ of Corti is maintained in the auditory pathway from the hair cell synapse to the 
auditory cortex and it is known as tonotopia. The inner hair cell synapses mainly transmit information 
about the acoustic environment, while the outer hair cells are involved in sound amplification. Auditory 
acuity can be enhanced by modulation of receptor activity through efferent suppressor pathways. This 
Figure 1.1 - Diagram of the inner ear. Adapted from Lang et al (3). 
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happens due to the integrations of the sensory input from the cochlea in the brain stem and auditory 
cortex 1,4.  
 
1.1.1. Inner Ear Disease 
Inner ear disease classically involves the membranous labyrinth and is characterized by the triad of 
sensorineural hearing loss (SNHL), tinnitus and vertigo. This may be caused by alterations in the inner 
ear hair cells, supporting cells or an aberrant inner ear homeostasis, altering the composition of 
endolymph and perilymph, affecting the integrity and functionality of the hair cells. Also, altered 
afferent and efferent auditory pathways may accompany or cause inner ear symptoms 5.  
 
1.2.  Auditory Disorders 
Hearing loss (HL) is the most common neurosensory disorder in humans, affecting 360 million 
people worldwide 6. In 2011, 120 000 people were estimated to have some degree of hearing loss in the 
Portuguese population 7. The World Health Organization (WHO) defines as disabling hearing loss when 
it is higher than 40 dB in the better ear (Annex A) 6.  
HL may be genetic, caused by single gene mutation or by a combinations of mutations in various 
genes, environmental, caused by trauma, medication, medical problems or environmental exposure, also 
it can be due to an association between genetic and environmental. HL can also be syndromic or non-
syndromic. Non-syndromic hearing loss (NSHL) can be inherited by an autosomal dominant mode, 
usually related to a delayed onset; an autosomal recessive, usually congenital and also mitochondrial 
and X-linked 8. Syndromic HL is accompanied by additional clinical features, such as anomalies of the 
eye, kidney, the musculoskeletal and the nervous systems and pigmentary disorders 9. 
HL can be present due to various dysfunctions and impairments in the inner ear, such as: impairment 
of stereociliar function, related to Usher syndrome 10; enlargement of the cochlear aqueduct, present, for 
example in Pendred syndrome 11; thickening of the stria vascularis, related to Alport syndrome 12; 
acoustic trauma, causing noise-induced HL. Also HL can be idiopathic, such as sudden deafness or 
caused by ototoxic medication, such as tuberculostatics, salicylic acid and aminoglycosides, that alters 
the function of inner ear structures and alter fine tuning of mechanoelectrical transduction 5. 
Tinnitus is the perception of a ringing tone within the ear without an external sound trigger. Tinnitus 
may be caused by alteration in the inner ear or auditory pathway or by vascular and muscular disorders, 
osseous disease or neoplasia. When the efferent system is affected by inner ear stressors it may cause 
tinnitus generation and maintenance 5. 
 
1.2.1. Age-related Hearing Loss  
Age-related hearing loss (ARHL) or presbycusis is a bilateral, progressive, mainly sensorineural 
hearing loss that occurs due to degenerative changes related to ageing of the cochlea and central auditory 
pathways, leading to high-frequency hearing loss and loss of speech discrimination 13–15. ARHL results 
from the cumulative effect of intrinsic and extrinsic factors, such as loud noise exposure, medical 
disorders, medications, anatomical degeneration and genetic susceptibility 13,15.  
ARHL shows considerable variation in age of onset, progression and severity 14. Currently, it affects 
over 70% of the world population over 65 years old 16. In 2015, there where 2,122,966 people over 65 
years old, in Portugal 17. United Nations projections show that the world’s elderly population (over 60 
years old) will double by 2050, surpassing 2 billion people 18. This comes to show that ARHL will 
continue to be a growing public health problem in the coming years. 
Genetic pre-disposition to ARHL is supported by studies conducted in mice 19–21. It was found that 
19 out of 80 inbred mouse strains showed early-onset hearing loss, while 16 of them revealed hearing 
loss at an older age. Further studies revealed 18 ARHL loci and 6 of the affected genes in mice have 
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been identified 19–21. The identification of mutations causing hearing loss in humans and their genetic 
screening is now practical and carried out in some clinical environments. Knowledge of these mutations 
will also allow susceptible individuals to have a protective behaviour towards their hearing 21.  
ARHL results in difficulty interpreting speech sounds, leading to a reduced ability to communicate. 
This translates into a physical and social impairment such as cognitive deficits, social isolation, 
dependence, frustration and reduced quality of life 22,23.  
Histopathologically, ARHL has been classified as sensory, neural, strial, metabolic, cochlear-
conductive, mixed or undetermined, based on temporal bone degeneration, age-related changes of the 
organ of Corti, ganglion cell, stria vascularis and basilar membrane and its correlation to audiometric 
data 24. 
Nowadays, ARHL rehabilitation relies mostly on the use of hearing aids, which focus on the 
peripheral auditory part. However, the success rate is limited due to the diversity of structural changes 
in the hearing pathway. People with peripheral deficits show the better response to hearing aids. 
Cochlear implant also shows satisfying results in cases of profound hearing loss 24 where the auditory 
pathways is still preserved. New targeted treatments may be developed through the understanding of the 
genetics of ARHL, as it may be indicative of the biological pathways of ARHL. 
 
 
1.2.1.1. GRM7 gene 
Glutamate metabotrophic receptor 7 (encoded by GRM7 gene), belongs to the family of G protein-
coupled receptors and is linked to the inhibition of the cyclic AMP cascade. L-glutamate is a fast 
excitatory neurotransmitter, that activates both ionotropic and metabotropic glutamate receptors. It also 
presents excitotoxic properties in the central nervous system, when it is released in excess or its recycling 
mechanism breaks down. This leads to a excitotoxic swelling of the postsynaptic target, due to a massive 
entry of cations and water, possibly resulting in postsynaptic neuron degeneration and loss of internal 
calcium homeostasis 25,26. 
In the mammalian cochlea, the best candidate for a neurotransmitter function at the synapses between 
the inner hair cells and the primary auditory neuron (type I spiral ganglion neurons) is glutamate.  
AMPA/kainate receptors are activated first and could be accountable for the synaptic transmission at 
low and moderate intensities and NMDA receptors seem to be secondarily activated by high-intensity 
sounds 27.  
The single-nucleotide variant or SNP rs11928865, located in the GRM7 gene, has been associated 
with ARHI in genome-association studies European and Chinese descendant populations 28,29. This gene 
is thought to be central to maintain glutamate synaptic transmission and homeostasis at the synapses 
between hair cells and the dendrites of afferent auditory nerve fibers. Excessive quantity of glutamate 
could be the mechanism mediating neurotoxicity in auditory neurons 30.  
 
1.2.1.2.  NAT2 gene 
Oxidative stress results from the accumulation of damage, due to an imbalance between the 
production and the removal of reactive oxygen species (ROS) and free radicals. Oxidative stress has an 
essential role in the ageing process and the diseases associated with ageing, such as ARHL 13,31. 
During the lifetime, the inner ear suffers a series of insults, for instance exposure to noise, drug 
influences, ear diseases and age related degeneration, which allied with a specific genetic background, 
such as antioxidant enzymes polymorphisms, might increase ROS levels, leading to hair cell damage 
13,31.  
In the adult cochlea there are numerous antioxidant enzymes, such as glutathione S-transferase, 
catalase and N-acetyltransferase. NAT2 (N-acetyltransferase 2) gene, located at chromosome 8p22, 
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codifies a N-acetyltransferase enzyme that detoxifies exogenic substrates by N–acetylation or O-
acetylation, contributing to the balance of oxidative status. NAT2 is highly polymorphic, resulting in 
intermediate, slow or rapid acetylators, having the latter two links to disease. For example, the missense 
substitutions of the NAT2 alleles, G191A (NAT2*14A), T341C (NAT2*5A), G590A (NAT2*6A) 
and/or G857A (NAT2*7A), are associated with slow acetylator phenotypes. These missense 
substitutions result in different functional characteristics, such as decreased protein expression 
(NAT2*5A and NAT2*6A) and reduced protein stability (NAT2*14A and NAT2*7A). Previous studies 
have linked the NAT2*6A polymorphism to ARHL in the Caucasian population 13,31.  
 
1.2.1.3. Mitochondrial DNA 
The mitochondria is vital in various cellular processes such as ATP production, β-oxidation of fatty 
acids, iron-sulphur cluster synthesis and apoptosis. The mammalian mitochondria harbour their own 
genome, that encodes 13 proteins , 2 rRNAs and 22 tRNAs 32.  
Mitochondrial DNA (mtDNA) mutations can lead to cellular energy conversion impairment and 
tissue dysfunction, being also tied to the pathophysiology of age-associated diseases, such as ARHL, 
and the ageing process itself. Morphology, abundance and oxidative phosphorylation activity changes 
are seen in ageing mitochondria 32. Recently, a study by Falah et al has described mtDNA copy number 
as a predictive biomarker for ARHL, as subjects with ARHL present lower mtDNA copy number than 
healthy individuals, which suggests that it occurs through alteration of mitochondrial function 33. 
Age-related mtDNA mutations increases in multiple human tissues such as heart, colon, skeletal 
muscle and brain. The spectrum of mutations is similar to nuclear DNA, including point mutations, 
insertions and deletions. A common age-related deletion mtDNA4977 deletion is usually associated 
with ageing. The levels of this mutation in human cochlear tissue was found to correlate with ARHL 
severity 32,34. 
mtDNA allows the division of the human population in ethnic groups, based on several discrete 
haplogroups. Haplogroups emerged due to the uniparental inheritance pattern of mtDNA and the 
negligible recombination at the population level, subdividing the human population through mutations 
acquired over time. The major haplogroups arose 40000-150000 years ago and have defined different 
human populations as they migrated out of Africa. The major European haplogroups (H, J, T and U) 
emerged 39000-510000 years ago. Currently, there are 20 haplogroups identified in the European 
community 35,36.   
It has been suggested that the presence of these “neutral” polymorphisms in mtDNA, defining 
different haplogroups might cause mild deleterious bioenergenic abnormalities, which contribute to the 
ageing process. A study by Manwaring et al found that haplogroups U and K (typically European) have 
a higher predisposition to ARHL 37,38. On the other hand, a study conducted by Bonneux et al found no 
significant association between any haplogroups and ARHL 38,39.  
 
1.3.Vestibular disorders  
Vestibular disorders (VD) are considered a group of diseases leading to transient or permanent loss 
of vestibular function 3. 
VD have a high clinical heterogeneity and overlapping symptoms among the different VD, which 
limits clinical characterization and phenotyping. According to their clinical presentation, three major 
syndromes can be distinguished: a) an episodic vestibular syndrome, such as motion sickness and 
vestibular migraine (VM); b) a progressive vestibular syndrome leading to bilateral vestibular 
hypofunction, including some rare disorders such as the cerebellar ataxia, neuropathy, vestibular 
areflexia syndrome (CANVAS); c) and diseases which include sensorineural hearing loss (SNHL) 
with a variable vestibular dysfunction, such as Meniere’s disease (MD) 3. 
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1.3.1. Meniere’s Disease  
MD is a multifactorial disorder that has its age of onset probably determined by the combined effect 
of genetics and environmental factors. Clinically, it is characterized by attacks of spontaneous vertigo 
usually associated with unilateral fluctuating SNHL, tinnitus and aural fullness. Vertigo attacks are 
typically more common in the first years of the disease, however HL and vestibular hypofunction are 
highly variable among patients. These patients can also develop bilateral SNHL, migraine, and systemic 
autoimmune diseases. This variability in the course of the disease makes MD phenotyping difficult 40. 
The prevalence of MD is highly different depending of the population in study, ranging from 34-190 
per 100,000 40. MD has a higher predominance in women and its age of onset ranges from the third to 
the seventh decades of life 40–42. 
Even though MD is considered multifactorial, there are three main hypothesis for its cause: genetic, 
autoimmunity and allergy. 
 The frequency of familial cases in European population is 5-15% and in Asian population (South 
Korean) 6.3%. Familial MD (FMD) studies suggest a genetic heterogeneity and an autosomal dominant 
pattern of inheritance with incomplete penetrance, however families with recessive inheritance have 
also been described. FMD is associated with an earlier onset and a tendency to more severe symptoms 
in successive generations 43,44. 
Several studies support that autoimmune mechanisms are associated to the pathophysiology of MD, 
such as: the finding of elevated levels of autoantibodies or circulating immune complexes in the serum 
of some patients 45–47; the association with alleles of DRB1 gene of the MHC reported in different 
populations; the association with a functional variant of LYP, a lymphoid protein phosphatase, which 
inhibits T cell receptors response in patients with bilateral ear involvement 48,49; and inner ear antigens 
with molecular weights of 28, 42, 58 and 68 kDa could be the main components inducing autoimmune 
MD in guinea pigs 50.   
The prevalence of diagnosed allergy is three times higher in MD patients than in the general 
population, being both inhalant and food allergens associated to MD 51.  Furthermore, MD patients have 
elevated levels of IgE (41.3%) compared to healthy controls (19.5%) 52. 
Derebery and Berliner described three theories relating allergy to MD that focus on inflammation 
within the endolymphatic sac (ES): 1) the ES fenestrated blood vessels could allow antigen entry, 
causing mast cell degranulation and inflammation; 2) circulating immune complexes may be 
deposited in the stria vascularis, resulting in an increased vascular permeability  and fluid 
imbalance; 3) viral antigen-allergic interaction, as viruses can damage epithelial surfaces, allowing 
an increase in antigen entry and increasing responsiveness to histamine 53. 
In support of the theory that the ES is a target for allergic activity, a study conducted in human tissue, 
has detected the presence of histamine receptor HRH1 in the epithelial lining of the ES and HRH3 
expressed exclusively in the sub-epithelial capillary network 54. 
There is not an effective treatment for MD, however patients may be helped by a combination of 
lifestyle and dietary changes, as well as medical therapy (drugs, surgery and physiotherapy) and 
psychological counselling. Some of the suggested lifestyle changes are allergy-avoidance, reduction of 
salt intake, avoidance of caffeine, tobacco and alcohol. Regarding medical therapy, several drugs may 
be administrated, such as: diuretics, betahistine, steroid therapy, that may be used to treat acute and 
chronic symptoms and gentamicin intratympanic injection, a destructive treatment that can be used in 
patients with intractable vertigo 55–57.  
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1.3.2. Vestibular migraine 
VM is defined by the occurrence of episodic vestibular symptoms and a history of migraine, with a 
temporal association in at least 50% of the attacks (Annex B) 58. However, it has only been considered 
a distinct disease since the new millennia, due to its high symptom overlapping with MD 3,59. 
VM has a population prevalence of about 1%, however it is considered underdiagnosed. The mean 
age of first occurrence is 37.7 years for women and 42.4 years for men. It is also 1.5-5 times more 
frequent in women than men 3,60. VM has been described in several families with an autosomal dominant 
inheritance 58.  
VM patients have a lack of sleep quality and high levels of depression, which causes a general 
decrease of health-related quality of life 60.  
VM patients have a favourable response to anti-migraine drugs, which supports an underlying 
migraine mechanism. However, this evidence is insufficient as it is based on uncontrolled clinical case 
series, thus the apparent efficacy may be due to confounding factors, such as placebo response, 
spontaneous improvement and multiple drug effect 58.  
There are families presenting familial hemiplegic migraine (FHM) and common migraine, which 
suggests a shared pathophysiology, as does VM. FHM has been linked to mutations in three genes: 
CACNA1A, ATP1A2 and SCN1A, which induce changes in the conductance of these voltage-gated ion 
channels. However, no evidence of an association with genes encoding ion channels linked to FHM has 
been found in VM. On the other hand, ATPase activity, leading to an increase in Na+ concentration has 
been linked to migraine pathophysiology. Therefore, genetic variation of ion channels and ion 
transporters, which regulate fluid homeostasis may underlie susceptibility to VM 3,61.  
Migraine is more common in patients with MD than in healthy controls. At times, VM and MD may 
be indistinguishable based only on medical history and symptoms, also it can present as a comorbidity. 
VM patients may present fluctuating hearing loss that does not progress to profound levels, tinnitus and 
aural pressure. Also, MD patients during attacks may experience migraine headaches, photophobia and 
migraine auras. Yet the pathophysiological relation between VM and MD is uncertain 58.  
 
2. Objectives  
The aim of this work is (1) to genetically characterize patients with ARHL, for GRM7 and NAT2 
genes and mtDNA haplogroups and (2) to investigate mold-induced immune response in VM patients 
and (3) to compare it to the response from MD patients. 
Determining ARHL genotypes could allow ARHL to be faced as an avoidable disease and not an 
obligatory age condition, also it could contribute to a molecular diagnostic and to estimate the risk of 
ARHL. 
Defining the effect of allergenic extracts from Penicillium and Aspergillus in proinflammatory 
cytokines and gene expression profile in VM patients peripheral blood mononuclear cells (PBMC) may 
allow to distinguish VM patients from MD patients. 
Both groups of results will lead to an increased knowledge on the genetic and environmental 
contribution to inner ear diseases, the main focus of this study. 
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3. Materials and Methods 
 
3.1. Patient Cohorts  
Two different patient cohorts were used: one for the study of ARHL and another for the study of VM 
and MD. 
3.1.1. ARHL Cohort  
A total of 483 Portuguese middle aged and elderly people were included in this study, with age 
comprised between 49 and 100 years old. The samples were obtained from institutions that have 
protocols with the Deafness Group – Translational and Biomedical Investigation Unit, BioISI, FCUL, 
such as senior universities and retirement homes. To avoid loss of anonymity, all individuals were coded 
with alphabet letters (PRE) and numbers, to distinguish them. Written informed consent was obtained 
from all participants. 
All patients involved in this study underwent audiometric examination, to assess the degree of 
hearing loss and a clinical history was obtained. The clinical variables studied were: cardiovascular 
disease, hypertension, diabetes, high cholesterol, tinnitus, thyroid disease, ototoxic disease, smoking 
habits, oncological disease, noise exposure, difficulty hearing in noisy spaces and hearing loss. HL (dB) 
is determined considering the average HL for the tested frequencies (500 Hz, 1000 Hz, 2000 Hz, 4000 
Hz) in the best ear. 
 
3.1.2. VM & MD Cohort 
A total of 73 samples from patients with VM and 115 samples from patients with MD were collected 
for this study. Recruitment was carried out in centres distributed over Spain. The experimental protocols 
of this study were approved by the Institutional Review Board in all participating hospitals and every 
patient signed a written informed consent. 
All patients underwent a complete neuro-otological evaluation and clinical history was obtained. The 
clinical variables studied were: gender, time course of disease, age of onset, family history of MD, 
hearing stage at diagnosis, type of headache, history of autoimmune disease, familial MD, 
cardiovascular risk factors (high blood pressure, type 2 diabetes, dyslipidemia and smoking) and 
Tumarkin crisis. Hearing stage was defined as a as four-tone average of 500 Hz, 1000 Hz, 2000 Hz and 
3000 Hz according to the American Academy of Otolaryngology Head and Neck Surgery (AAO-HNS) 
(stage 1, ≤ 25 dB; stage 2, 26-40 dB; stage 3, 41-70 dB and stage 4, >70 dB). The types of headache are 
migraine and tension-type headache. Migraine can be accompanied by or without aura.  
 
3.2.  gDNA Extraction 
gDNA was extracted from blood samples collected in FTA® cards (Whatman, GE Healthcare), the 
blood sample was collected through index finger skin puncture. FTA® cards were stored at room 
temperature. gDNA extraction protocol was followed by the NZY Tissue gDNA Isolation Kit 
(NZYTech, Lisbon) suppliers recommendations. 
 
3.3.HSV1 and NAT2 PCR 
The HVS1 of the mitochondrial genome was amplified and sequenced in order to identify 
polymorphisms. This region was amplified from position 15975 to 16515. In table 3.1, the primers used 
for the PCR reaction are identified. 
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Table 3.1- mtDNA primers and respective size of the amplicon. 
Primer Sequence Amplicon size (bp) 
HVS1-F 5’- CTCCACCATTAGCACCCAAAGC-3’ 
540 
HVS1-R 5’- TGAAGTAGGAACCAGATGTCGG-3’ 
 
The PCR reaction mix had the primers at 10 μM, KAPA2G Robust HotStart ReadyMix (2X) (0.5 
U/25 µl of reaction) (KapaBiosystems, GrISP, Porto), sterile ultrapure water and DNA. In every PCR a 
negative control was added, without DNA, to confirm de absence of contaminants. The PCR conditions 
are present in annex B.  
NAT2 gene was amplified and sequenced in order to identify seven SNPs: rs1799930, rs1799931, 
rs1801280, rs1208, rs1041983, rs1799929 and rs1801279, that allow to define a haplotype and the 
corresponding acetylation phenotype. NAT2 gene was amplified from position 13886 to 14724, through 
a PCR reaction using the primers shown in table 3.2.  
 
Table 3.2 – Primers used to amplify NAT2 gene and respective amplicon size 
Primer Sequence Amplicon size (bp) 
NAT2-F 5’- CATTGTGGGCAAGCCA -3’ 
839 
NAT2-R 5’- AACGTGAGGGTAGAGAGG -3’ 
 
The PCR reaction mix had the primers at 10 μM, 2x Kapa 2G Fast Hot Start Ready Mix (0.5 U/25 
µl of reaction) (KapaBiosystems, GrISP, Porto), sterile ultrapure water and DNA. In every PCR a 
negative control was added, without DNA. The PCR conditions are present in annex B.  
All PCR products were observed in electrophoresis, with 2% agarose gel ((SeaKem® LE Agarose, 
Lonza) and in TBE buffer 0.5X. Midori Green Advanced DNA Stain (GrISP, Porto) was used as DNA 
intercalating agent, which is observable under blue light. The gel was photographed with the 
photographic system FastGene® FAS Digi (GrISP, Porto). To compare DNA fragment size it was used 
GRS Ladder 100 bp (GrISP, Porto). The loading buffer consisted of a 0.25% Bromophenol Blue, 0.25% 
Xylene cyanol, 95% Formamide and 10mM Sodium hydroxide solution. 
 
3.4.  Sequencing and Sequence Analysis 
The PCR products were sent to a company STAB Vida, which purifies and sequences the samples. 
mtDNA sequences were analysed  with Chromas Lite 2.1.1 software and compared to the reference 
sequence J01415.2, with NCBI’s BLAST program. The mtDNA haplogroups were estimated by the 
mtDNA Haplogroup Analysis software 62.  
NAT2 sequences were analysed with the alignment tool Mega6 and compared to the reference 
sequence NG_012246.1. NAT2 haplotypes and genotypes were determined considering the N-
acetyltranferases database. NAT2 phenotypes were determined with NAT2PRED software 63.  
 
3.5. Genotyping with Real-time PCR 
The allelic discrimination of GRM7’s SNP rs11928865 was conducted by real-time PCR, with ABI 
StepOne™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The 10 μL reaction 
volume included 5 μL of TaqMan Genotyping Master Mix (Applied Biosystems), 0.5 μL of TaqMan 
Probe Mix (Applied Biosystems), 0.5 μL of ultrapure sterile water and 4 μL of DNA. The PCR 
conditions are in annex C.  
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3.6. PBMC Isolation and Stimulation  
Peripheral blood was diluted 1:1 with 1× PBS and disposed carefully onto the corresponding 25:15 
volume of Lymphosep, Lymphocyte Separation Media (Biowest, Nuaillé, France). Samples were 
centrifuged for 20 minutes at 2000 rpm to separate blood content. PBMC were collected and washed 
with 1× PBS and cultured in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (Biowest, 
Nuaillé, France) and plated at 1.25x106 cells/mL in 6-well plates. In some experiments, fungus extract 
was added (2 Allergenic Extract-Mix fungus containing, in one case, 4 equal parts of Mix Aspergillus 
(oryzae, repens, niger and terreus) and in the other case, 4 equal parts of Mix Penicillium 
(brevicompactum, expansum, notatum and roqueforti)). The combinations were dialyzed to remove 
phenol using Tube-o dialyzer (VWR International, Radnor, PA, USA) against deionized distilled water. 
Each subject had a well per condition and 1.25 x 106 PBMC/mL was stimulated with 5 μg/mL dialyzed 
mixed fungus. PBMC were incubated during 16 h at 37°C in 7% CO2 and compared with cultured, 
unstimulated PBMC. The optimal concentrations of these mixtures were identified for previous studies 
conducted by the group. At the end of all incubations, PBMC were centrifuged, RNA and proteins 
harvested and supernatants were collected and stored at -80 °C. 
 
3.7. RNA Extraction 
RNA was isolated using the RNeasy® Mini Kit (Qiagen) following the manufacturer’s protocol. RNA 
concentration was measured on a Nanodrop (NanoDrop Technologies Inc.,Wilmington, DE, USA). 
RNA quality was checked using Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, 
Germany). 
 
3.8. Quantitative PCR 
One-hundred ng of RNA was converted into cDNA using Maxima First Strand cDNA Synthesis Kit 
for RT-qPCR with dsDNase (Thermo Fisher Scientific) and cDNA samples were diluted to 2 ng/μL for 
the qPCR assays. 
The quantification of IL-1β, IL-1RN, IL-6, TNFα and Glyceraldehyde 3-phosphate Dehydrogenase 
(GAPDH) gene expression was conducted by quantitative PCR (qPCR) from each cDNA sample. 
Reactions were made with a final primer (table 3.3) concentration of 1 μM in a final volume of 20 μL 
and using Brilliant III Ultra-Fast SYBR® GreenQPCR Master Mix (Agilent Technologies) as detection 
system under the PCR conditions present in table 8.5 (Annex C), using an ABI 7900 HT Fast Real-Time 
PCR Systems (Life Technologies). No template controls were included in all qPCR plates. To check for 
reproducibility, four technical replicates were carried out for each sample. GAPDH was used as an 
endogenous expression control. 
 
Table 3.3 – Primers used to amplify cDNA of each cytokine and respective amplicon size. 
Primer Sequence Amplicon size (bp) 
IL1B_fw 5’- AATCTCCGACCACCACTACAG - 3’ 
217 
IL1B_rv 5’ – GTTCAGTGATCGTACAGGTGC – 3’ 
IL6_fw 5’ – CCACTCACCTCTTCAGAACGA – 3’ 
211 
IL6_rv 5’ – TGATTTTCACCAGGCAAGTCTC – 3’ 
TNFa_fw 5’ - TCTTCTCCTTCCTGATCGTGG – 3’ 
186 
TNFa_rv 5’ – GAGGGTTTGCTACAACATGGG – 3’ 
IL1RN_fw 5’ – GGATTCACAAGACGATCTGCC – 3’ 
220 
IL1RN_rv 5’ – ATCACCAGACTTGACACAGGA - 3’ 
GAPDH_fw 5’ – ATCACCATCTTCCAGGAGCGAGA – 3’ 
193 
GAPDH_rv 5’ – CATGGTTCACACCCATGACGAACA - 3’ 
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3.9. Extracellular Cytokine Level Determination  
Conditioned supernatants were collected and stored at –80 ºC until a sufficient number of samples 
were acquired. Frozen samples were thawed immediately prior to analysis and none of the samples 
underwent repetitive freeze-thawing cycles prior to analysis. IL-1β, IL-6, IL-1RA and TNFα levels in 
conditioned supernatant were quantified simultaneously with a commercially available Multiplex Bead-
Based Kit (EMD Millipore, Billerica, MA, USA), in accordance with the kit-specific protocols provided 
by Millipore, using a Luminex 200 (Luminex Corp., Austin, TX, USA) and read with Luminex x 
PONENT 3.1 software (Luminex Corp.). The minimum detection limit for the assay was 0.14pg/mL 
and the maximum 10000 pg/mL. Samples with readings below or above these levels were assigned 
values of 0pg/mL for the minimum value or 10000pg/mL for the maximum value. The reliability of the 
measurements were previously determined for previous studies conducted by the group, by calculation 
of the Intraclass Correlation Coefficient (ICC) and sandwich-ELISA (>80%). 
 
3.10. Expression Array  
Expression levels were measured using the HumanHT-12 v4 Expression BeadChip (Illumina Inc.) 
with 500 ng of total RNA and processed with the high resolution scanner iScan (Illumina Inc.). Limma 
R package from Bioconductor was used for expression data analysis, normalization and differential 
expression analysis. 
Signalling pathway analysis was performed using Ingenuity Pathways Analysis (IPA®, Qiagen, 
Venlo, Netherlands, http://www.ingenuity.com/products/ipa) software. Core analysis tool was executed 
using the DEG with an adjusted p-value cut-off of 0.001. 
 
3.11. Statistical Analysis  
A descriptive analysis was conducted using SPSS software (SPSS Inc.) for both cohorts. 
The audiograms were analyzed considering the best ear (estimated based on the lowest average of 
frequencies of 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz). For the results from ARHL cohort, Chi-square 
Test was used for general association between two variables were used. Kruskal-Wallis (for more than 
2 groups) tests were employed to compare hearing thresholds.  All the results were analysed through 
logistic regression model, where age was considered as control for all the others variables.  
For the results from VM and MD cohort, quantitative variables were compared using Student’s 
unpaired T-test. Qualitative variables were compared using cross tables and Fisher’s exact test. 
The level of significance considered was p-value<0.05 for both cohorts.  
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4. Results 
 
4.1. Demographic Results 
A descriptive analysis was conducted for both cohorts. Demographic results from ARHL cohort were 
analysed considering the influence of the variables on hearing loss. VM and MD cohorts were compared 
to determine differences between the demographics of the diseases. 
 
4.1.1. ARHL Cohort  
Due to the nature of the questionnaire, it was not possible to obtain full information from the 483 
individuals, therefore on table 4.1 the percentage of each variable is relative to the number of answers 
obtained. This cohort is composed mostly by women and the mean age is 76.49.8 years. A great 
majority of the individuals also show difficulty of listening in noisy environments (69.1%) and have 
tinnitus (68.5%).  
 
Table 4.1 - ARHL cohort descriptive analysis of demographics and clinical history. 
Variables ARHL (N (%) 
Age, mean (SD) 76.4 (9.8) 
Sex (female %) 332 (70.2) 
Noise exposure 135 (33.3) 
Difficulty hearing in noisy spaces 268 (69.1) 
Cardiovascular disease 115 (29.0) 
Hypertension 250 (63.0) 
Diabetes 106 (27.6) 
High cholesterol 221 (57.1) 
Tinnitus 258 (68.5) 
Thyroid disease 61 (15.9) 
Ototoxic disease 63 (21.6) 
Smoker 95 (23.3) 
Oncological disease 69 (16.6) 
 
The effect of demographics and comorbidities was tested for each of the hearing frequency 
considered. It was evident that there was a significant difference for sex, age, hypertension and 
cardiovascular disease, as seen on table 4.2. The effect of sex it is evident on lower frequencies (250 Hz 
and 500 Hz) where men have better hearing and at 4000 Hz there is an inversion and women turn into 
the better listeners (figure 4.1).  
They were then categorized by mean HL in the best ear according to the WHO classification, which 
revealed that 33% of the sample has normal hearing and 67% of the sample have hearing loss (34.5% 
have mild HL, 27.5% have moderate HL and 5% have severe to profound HL). The same characteristics 
where analysed to see if they have an effect on the prevalence of HL (Annex D), which showed that age, 
cholesterol, hypertension and cardiovascular disease have an effect on HL. Moreover, a multivariate 
logistic regression controlled by age was conducted, which showed the effect of cholesterol and diabetes 
on HL (table 4.3). This is, for the same age, people with cholesterol show a 40% inferior probability of 
HL compared to people without cholesterol. People with diabetes show a 77% superior probability of 
HL than people without diabetes 
 
 12 
 
Table 4.2 - Effect of demographic and clinical features on HL per frequency (Hz) 
Characteristic p-value for each frequency 
250 Hz 500 Hz 1000 Hz 2000 Hz 4000 Hz 8000 Hz 
Sex 0,032* 0,028* 0,166 0,493 0,001* 0,148 
Age <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* 
Cholesterol 0,100 0,388 0,247 0,078 0,017* 0,013* 
Hypertension 0,005* 0,001* 0,005* 0,018* 0,020* 0,020* 
Tinnitus 0,204 0,163 0,532 0,757 0,803 0,683 
Diabetes 0,246 0,838 0,321 0,201 0,203 0,801 
Smoking 0,010* 0,045* 0,057 0,041* 0,395 0,170 
Cardiovascular Disease 0,004* 0,002* 0,018* 0,057 0,491 0,331 
Noise Exposure 0,392 0,592 0,618 0,682 0,164 0,438 
Ototoxic Medication 0,284 0,196 0,428 0,210 0,392 0,126 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3 - Multivariate logistic regression controlled by age. 
Characteristic OR p-value 
Sex (Masculine) 1.34 0.294 
Cholesterol (Yes) 0.60 0.077* 
Hypertension (Yes) 1.23 0.487 
 Tinnitus (Yes) 1.14 0.664 
Diabetes (Yes) 1.77 0.089* 
 Smoking (Yes) 1.29 0.438 
Cardiovascular Disease (Yes) 1.51 0.225 
Noise Exposure (Yes) 1.46 0.203 
Ototoxic Medication (Yes) 0.92 0.831 
 
4.1.2. VM & MD cohort 
It was not possible to obtain full information from all the patients, therefore on table 4.4 and table 
4.5 the percentage of each variable is relative to the number of answers obtained.  
VM patients have a mean age of onset of 37.115.0 and have slightly more frequent migraine with 
aura. These patients have no history of Tumarkin crisis (table 4.4). On the other hand, MD patients have 
a higher age of onset (48.314.4 years) and have least frequently headaches, also they have a slight 
predominance of female affected patients (table 4.5). 
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Figure 4.1 - Effect of sex on HL (dB) for each tested frequency (Hz) 
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Table 4.4 - VM patients' descriptive analysis for demographics and clinical history. 
Variables VM 
Age, meanSD 48.215.0 
Sex (female) n (%) 51 (75) 
Age of onset (SD) 37.1 (17.1) 
     Age of onset <40, n(%) 41 (60.3) 
Time course (years), meanSD 10.49.8 
Headache (%) 67 (98.5) 
     Type of headache (migraine), n (%) 64 (94.1) 
          Type of migraine (with aura), n (%) 28 (57.1) 
Smoking, n (%) 13 (19.1) 
High blood pressure, n (%) 18 (32.7) 
Tumarkin crisis, n (%) 0 (0) 
 
Table 4.5 - MD patients' descriptive analysis for demographics and clinical history. 
Variables MD 
Age, meanSD 60.712.6 
Sex (female %) 67 (58.8) 
Age of onsetSD 48.314.4 
     Age of onset <40, n(%) 32 (28.6) 
Time course (years), meanSD 10.39.0 
Affect ear (unilateral) n (%) 73 (64.0) 
Headache (%) 42 (39.6) 
     Type of headache (migraine), n (%) 22 (48.9) 
Familial md, n (%) 10 (9.7) 
Hearing stage  
1 9 (8.2) 
2 31 (28.2) 
3 51 (46.4) 
4 19 (17.3) 
Autoimmune disease (%) 16 (17.6) 
Smoking, n (%) 17 (16.7) 
High blood pressure, n (%) 26 (26.5) 
Dyslipemia, n(%) 21 (27.6) 
Type 2 diabetes 9 (9.8) 
Tumarkin crisis, n (%) 18 (17.6) 
 
A comparison between VM and MD patients revealed that there are differences between the age of 
the patients, age of onset of the disease, prevalence of females affected, frequency of headaches and 
migraine (table 4.6). However, when comparing VM to the specific MD type 4 64, characterized by the 
presence of migraine in all cases, it is observed that there are only significant differences in age of the 
patients and the age of onset of the diseases (table 4.6). 
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Table 4.6 - Comparison of VM patients’ demographics and clinical history to MD patients and MD type 4 patients. 
Variables VM MD p-value MD type 4 p-value 
Age, meanSD 48.215.0 60.712.6 1.18×10-8 60.712.2 0.0104 
Sex (female %) 51 (75) 67 (58.8) 0.023 9 (81.8) 0.476 
Age of onsetSD 37.117.1 48.314.4 5.0×10-6 51.913.1 0.00760 
Time course (years), 
meanSD 
10.49.8 10.39.0 0.960 5.65.1 0.121 
Headache (%) 67 (98.5) 42 (39.6) 8.18×10-18 11 (100) 0.861 
Type of headache 
(migraine), n (%) 
64 (94.1) 22 (48.9) 4.2×10-8 11 (100) 0.542 
 
4.2. GRM7 gene 
From the total of 467 people genotyped by real-time PCR for the GRM7 SNP rs11928865, only 337 
individuals had full audiogram information, therefore only these were considered for the analysis. In 
table 4.7, it is possible to observe that the most common genotype is T/T with a corresponding mean HL 
of 35.0115.61 dB and the least frequent genotype is A/A with a mean HL of 29.7016.03 dB.  
The genotype effect was tested for each 
tested hearing frequency and as observed in 
figure 4.2, there is a significant difference at 
8000 Hz (p-value=0.048). However, when 
categorized by mean HL in the best ear 
according to the WHO classification and 
tested to evaluate the effect of GRM7 SNP 
rs11928865 genotype on HL there were no 
significant differences (p-value=0.133). 
Also, a multivariate logistic regression 
controlled by age showed that comparing to 
A/A genotype, A/T genotype had a 1.93 
times higher hearing loss risk and T/T 
genotype a 2.08 times higher hearing loss 
risk, but this was not statistically different 
(table 4.8). 
 
Table 4.7- Distribution of individuals according to GRM7 rs11928865 and its associated mean HL  Standard deviation 
(SD). 
Genotype N (frequency) Mean HL SD (dB) 
A/A 21 (6.2%) 29.7016.03 
A/T 115 (34.1%) 33.9516.01 
T/T 201 (59.6%) 35.0115.61 
 
Table 4.8 - Logistic model applied to HL controlled by age, considering GRM7 SNP rs11928865 A/A genotype as reference 
GRM7 genotype OR (95% CI) p- value (Wald) 
A/T 1.93 (0.69,5.52) 0.210 
T/T 2.08 (0.77,5.68) 0.147 
 
250 500 1000 2000 4000 8000
0
10
20
30
40
50
60
70
80
90
100
A/A
A/T
T/T
*
Frequency (Hz)
H
e
a
ri
n
g
 L
e
v
e
l 
(d
B
)
Figure 4.2 – Effect of GRM7 SNP rs11928865 genotype on HL (dB) 
for each tested frequency (Hz). 
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4.3. NAT2 gene 
From the total of 442 people genotyped by real-time PCR for 7 SNPs of NAT2: rs1799930, 
rs1799931, rs1801280, rs1208, rs1041983, rs1799929 and rs1801279, only 334 individuals had full 
audiogram information, therefore only these were considered for the analysis. 
The most common NAT2 haplotypes are NAT2*4/NAT2*5U (21%) and NAT2*4/NAT2*5B (18%) 
(annex E). As some of the haplotypes are not sufficiently represented to conduct a statistical analysis, 
we only considered the ones that were present in at least 10 individuals. It was observed a statistical 
difference (p-value=0.037) between NAT2 haplotypes at a 250 Hz frequency. When analysed more 
deeply it was determined that this difference is found between haplotypes NAT2*4/NAT2*6A and 
NAT2*5B/NAT2*5B (adjusted p-value=0.012). Likewise, a multivariate logistic regression controlled 
by age showed that there was a statistically significant difference for NAT2*4/NAT2*5A, when using 
NAT2*6A/NAT2*6A as reference, as seen on table 4.9. However, when tested using the WHO 
classification, no statistical differences were found (p-value= 0.963).  
In table 4.10, it is possible to observe that an higher HL belongs to a slow acetylation phenotype and 
a lower HL belongs to a rapid acetylation phenotype, however no statistically significant differences 
were found when testing for each frequency independently (p-value=[0.309;0.635]) or for HL by the 
WHO classification (p-value=0.639). Likewise, a multivariate logistic regression controlled by age 
showed no differences (for R p-value=0.540 and for S p-value=0.652). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.9 - Logistic model applied to HL controlled by age, considering the haplotype NAT2*6A/NAT2*6A as reference 
NAT2 haplotype OR (95% CI) p- value (Wald) 
4/4 0.180 (0.34, 4.21) 0.079 
4/5A -0.073 (0.17, 5.19) 0.007 
4/5B 0.390 (0.55, 3.99) 0.589 
4/5U 0.404 (0.53, 4.21) 0.588 
4/6A 0.185 (0.43, 3.34) 0.126 
5B/5B 0.404 (0.55, 4.07) 0.628 
 
 
Figure 4.3 - Effect of NAT2 haplotypes on HL (dB) for each tested frequency 
(Hz). 
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Table 4.10 - Distribution of individuals according to NAT2 phenotype and associated mean HLSD. 
Phenotype N (frequency) Mean HLSD (dB) 
Slow (S) 171 (51.19%) 34.7915.88 
Intermediate (I) 140 (41.92%) 33.5415.59 
Rapid (R) 23 (6.89%) 30.7115.17 
 
4.4.mtDNA 
From the total of 444 people’s DNA sequenced for HVS1 of mtDNA, only 336 individuals had full 
audiogram information and were considered for the analysis. The most common haplogroup detected in 
our sample was haplogroup H and the least common haplogroup M and haplogroup Y (annex F). As 
some of the haplogroups are not sufficiently represented to conduct a statistical analysis, we only 
considered the ones that were present in at least 12 individuals. On table 8.8 (Annex F), it is possible to 
observed that of the tested haplogroups, the one with the highest hearing loss is haplogroup T and the 
one with the lowest hearing loss is haplogroup L, yet no statistically significant differences were found 
when testing for each frequency independently (p-value=[0.136;0.747]) or for HL by the WHO 
classification (p-value=0.979). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4- Hearing loss of the most common haplogroups by tested 
frequencies. 
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4.5. qPCR 
qPCR was conducted to determine the expression levels of IL-1β, IL-1RN, IL-6 and TNFα genes in 
VM patients and healthy controls. 
Fold-change values of cytokine expression levels were determined between stimulated and non-
stimulated PBMC of controls and VM patients. As seen in table 4.11, VM patients present higher fold-
change values for IL-1, IL-1RN and IL-6, but not for TNFα, although none of them are significantly 
different.  
Fold-change values of cytokine expression levels between VM patients and controls were calculated, 
and as observed in figure 4.5 when stimulating PBMC with Aspergillus there is a tendency for an higher 
expression of IL-1, TNFα and IL-6, being the last significantly different. Furthermore, when stimulating 
PBMC with Penicillium there is not a change in the expression levels of either cytokines. 
 
Table 4.11 –Fold-change values for cytokine expression levels between stimulated and non-stimulated PBMC of controls and 
VM patients. 
Cytokine Stimulation Case mean 2-ΔΔCt p-value 
IL-1 
Aspergillus 
Control 2,55E+02 
0.631 
VM 9,40E+02 
Penicillium 
Control 2,06E+02 
0.536 
VM 6,00E+02 
IL-1RN 
Aspergillus 
Control 4,52E+02 
0.604 
VM 7,00E+08 
Penicillium 
Control 1,89E+02 
0.940 
VM 2,03E+02 
IL-6 
Aspergillus 
Control 5,08E+01 
0.053 
VM 9,51E+02 
Penicillium 
Control 8,43E+02 
0.817 
VM 1,04E+03 
TNFα 
Aspergillus 
Control 2,20E-01 
0.061 
VM 1,97E+00 
Penicillium 
Control 3,41E-01 
0.266 
VM 1,33E+00 
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Figure 4.5 - Fold-change values for cytokine expression levels between 
patients with VM and controls. * - p-value=0.048. 
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4.6. Extracellular Cytokine Levels 
The level of IL-1β, IL-1RA, IL-6 and TNFα present in the cells supernatant was determined using a 
commercially available Multiplex Bead-Based Kit.  
IL-1RA levels were significantly higher in VM patients than in controls (figure 4.6A). IL-6 and 
TNFα levels were significantly higher in VM patients when compared to controls, with both stimulations 
(Aspergillus and Penicillium), however the difference is significantly higher when stimulated with 
Penicillium (figure 4.6B and 4.6C). 
Previous studies in our group have determined 
that MD patients can be grouped according to their 
IL-1β and TNFα levels. With this knowledge, we 
decided to compare VM patients with the different 
categories of MD patients (unpublished findings). 
When comparing the basal levels of VM to MD 
with low IL-1β and TNFα levels, we can observe that 
there is only a significant difference between VM 
and MD with low levels of TNFα in IL-1RA (figure 
4.7A). 
When comparing the stimulated levels (with 
Aspergillus and Penicillium) of VM to MD with low 
IL-1β and TNFα levels, we can observe that there is 
a significant difference in the levels of IL-1RA and 
IL-6 (figure 4.7B and 4.7C). 
From the comparison of the basal levels of VM to 
MD with high IL-1β and TNFα levels, we can 
observe that there is a significant difference between 
the levels of all evaluated cytokines (Figure 4.7D). 
However, the stimulated levels with Aspergillus are 
only significantly different when comparing the 
levels of IL-1RA of VM and MD with high TNFα 
levels (figure 4.7E). Also, the stimulated levels with 
Penicillium are significantly different when 
comparing the levels of IL-1RA and IL-6 of VM and 
MD with high TNFα levels (figure 4.7F). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6- Cytokine levels in VM patients and controls. 
A- basal levels; B- stimulated with Aspergillus; C- 
stimulated with Penicillium 
* - p-value < 1×10-³; ** - p-value [1×10-³ - 1 ×10-5];  
*** - p-value > 1 ×10-5 
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Figure 4.7 - Cytokine levels in VM patients and MD patients. A - basal levels (MD with low cytokine levels); B - stimulated 
with Aspergillus (MD with low cytokine levels); C - stimulated with Penicillium (MD with low cytokine levels);  
D - basal levels (MD with high cytokine levels); E - stimulated with Aspergillus (MD with high cytokine levels); F - stimulated 
with Penicillium (MD with high cytokine levels). * - p-value < 1×10-³; ** - p-value [1×10-³ - 1 ×10-5]; *** - p-value > 1 ×10-
5 
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4.7.Gene Expression  
We compared gene expression profiles in non-treated PBMCs from VM patients with MD patients 
with high () and low () levels of cytokines and also with healthy controls. We performed a Core 
analysis from IPA® software using all genes from the expression profiles. The Upstream analysis within 
the Core analysis identifies upstream regulators that are predicted to be activated or inhibited based on 
an activation z-score. The comparisons between gene expression profiles in non-treated PBMCs of VM 
patients and MD patients with -level of cytokines and also between VM patients and healthy controls 
revealed no statistically significant differences. However, there are statistically significant differences 
between VM patients and MD patients with -level of cytokines. Based on the pathways retrieved, we 
could predict the involvement of B-cell maturation, cytokine production and dendritic cell maturation 
(table 4.12). 
 To further characterize the role of mold in inflammatory response, VM patients PBMCs were 
cultured and their responses to mold were directly compared with stimulated PBMC from healthy 
volunteers. Based on the pathways retrieved (table 4.13), we could predict that the stimulation by 
Aspergillus and Penicillium involves inflammation and cytokine production as well as apoptosis 
signalling. 
Additionally, we compared the response from VM patients stimulated PBMC and MD patients 
stimulated PBMC (table 4.14 and table 4.15), which also revealed the involvement of upstream 
regulators that take part in differentiation, activation and regulation of T-cells, B-cell development, 
dendritic cell maturation and allergy. 
 
Table 4.12 - Canonical pathways state in non-stimulated MD patients with -level of cytokines compared to VM patients. 
 
Table 4.13 - Canonical pathways involved in VM exclusive to stimulation with Aspergillus or Penicillium. 
 
 
 
 
 
 
 
Canonical Pathway p-value State 
CD28 Signaling in T Helper Cells 1.77×10-12 Inhibited 
iCOS-iCOSL Signaling in T Helper Cells 3.49×10-9 Activated 
Dendritic Cell Maturation 3.79×10-9 Activated 
PI3K Signaling in B Lymphocytes 3.87×10-9 Inhibited 
Pathway 
Aspergillus Penicillium 
State p-value State p-value 
IL-8 Signaling Inhibited 1,59×10-7 Activated 6.59×10-9 
Death Receptor Signaling Inhibited 6,70×10-7 Inhibited 4.05×10-7 
Toll-like Receptor Signaling Inhibited 7,76×10-7 Inhibited 1.13×10-5 
NFkB Signaling Inhibited 8,46×10-7 Inhibited 3.73×10-6 
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Table 4.14 - State of upstream regulators in MD comparing to VM, exclusive to each stimulation (p-value< 10-5). 
Stimulation Upstream Regulator p-value State 
Aspergillus 
RICTOR 3.82×10-7 Inhibited 
TCR 1.32×10-11 
Activated XBP1 6.89×10-8 
E2F1 9.50×10-7 
Penicillium 
IL1RN 6.44×10-10 
Inhibited PTGER4 2.17×10-9 
TRIM24 2.10×10-8 
PRL 9.15×10-13 
Activated 
HGF 3.34×10-12 
IFNA2 1.00×10-11 
STAT1 4.97×10-11 
CD40LG 7.90×10-11 
TLR3 3.05×10-10 
IRF3 5.63×10-10 
 
Table 4.15 - State of upstream regulators in MD comparing to VM, common to both stimulations (p-value<10-5). 
Upstream Regulator 
p-value 
(Aspergillus) 
p-value 
(Penicillium) 
State 
IFNG 2.07×10-14 3.03×10-27 
Activated 
TNF 1.40×10-15 9.18×10-28 
MYC 4.94×10-10 2.9×10-11 
IL2 5.19×10-11 5.54×10-23 
NFkB (complex) 1.62×10-9 7.69×10-7 
TLR4 2.47×10-8 1.63×10-14 
IL1A 1.04×10-7 1.28×10-7 
HIF1A 1.96×10-7 1.27×10-10 
Interferon alpha 1.06×10-6 1.90×10-15 
GFI1 3.02×10-7 3.33×10-10 
Inhibited CD3 2.00×10-6 4.45×10-11 
CD28 2.76×10-6 1.34×10-9 
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5. Discussion  
The present work is focused in different aspects related to inner ear diseases in order to achieve a 
better knowledge on it. The first part of this work, considers a sample of individuals with ARHI in the 
Portuguese population and the second part considers a sample individuals with vestibular episodic 
syndrome (VM and MD) from the Spanish population. 
The individuals of the Portuguese sample underwent a clinical history questionnaire, hearing 
evaluation and genetic screening analysis. These individuals were middle aged and elderly people aged 
between 49 and 100 years, screened in an attempt to find factors that might contribute to the 
identification of risk factors and consequently to the diagnosis of ARHL and inform future therapeutic 
interventions. 
Our results show that there are significant differences in HL for age, for each frequency and overall 
HL (table 4.2 and table 4.3), as expected. A study by Lin et al (2011) in the United States of America 
population, reported a HL prevalence of 63.1% in participants over 70 years 65. Considering the increase 
in life expectancy, these results present obvious consequences of ageing. 
We found that men have significantly better hearing for lower frequencies (250 Hz and 500 Hz) and 
women at high frequencies (4000 Hz), in concordance with previous results. Lin et al (2011) studied the 
association between sex and HL applying different frequency ranges: standard [500–2000 Hz] speech 
[500–4000 Hz] and high frequency [3000–8000 Hz] and found that male sex was associated to greater 
hearing loss at speech frequency and high frequencies 65. On the other hand, a study by Homans et al 
(2016) found that men had overall significantly better thresholds at the lower frequencies, whereas 
women had overall significantly better thresholds at the higher frequencies 66, which is in agreement 
with our findings since we observe an gender reversal phenomenon of ARHL. This may be explained 
by the fact that women have a lifestyle that is more similar to men in comparison with 20 to 30 years 
ago, suggesting that the environment and lifestyle have an essential effect on the development of ARHL 
66. 
Distinct types of comorbidities have been related to presbycusis. When these were studied for the 
influence in each hearing frequency, we found that cholesterol (4000 Hz and 8000 Hz), hypertension 
(250 Hz-8000 Hz), smoking (250 Hz, 500 Hz and 2000 Hz) and cardiovascular disease (250 Hz-1000 
Hz) had effect on HL. However, when adjusting the data to a multivariant model controlled by age, it is 
only observed a statistically significant difference for cholesterol and diabetes: patients with high 
cholesterol levels have a 40% lower probability of HL and patients with diabetes have a 77% higher 
probability of HL, for patients with the same age.  
Lee et al (2013) and Sogebi et al (2017) reported that smoking had a positive correlation with HL, 
which is in agreement with our findings 67,68. However, reports that smoking tobacco have no effects on 
HL have also been made by Bener et al (2016) 69, but on the other hand they found a relation between 
high levels of cholesterol and HL69.  
Our results on the effect of cholesterol and HL could also be related with specific medication for the 
pathology and not directly with lipid concentration. Gopinath et al (2011) found that serum lipids were 
not associated to prevalence of HL, however people using statin (cholesterol lowering medication) were 
48% less likely to have HL compare to those not using the treatment 70. On the other hand, Lee et al 
(2015) concluded that their study partially supported the absence of a relevant relationship between high 
frequency HL and low high density lipoprotein- cholesterol, as they only found a small association 71. 
Anatomically, high cholesterol affects the inner ear blood supply and the lateral wall stiffness of the 
cochlear outer hair cells, therefore further studies should be conducted to assess the effect of cholesterol 
on ARHL, including very high frequency HL (8-16 kHz) 71,72.  
Various studies, conducted in very different settings, such as a Nigerian population, an highly 
endogamous population and an American population have described being hypertensive and diabetic as 
risk factors for HL, which support the finding of this study 65,67,69,73. 
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Hutchinson et al (2010) found that old adults with high cardiovascular health had the best hearing 
ability, suggesting the protective effect of cardiovascular fitness on hearing 74. Additionally, McKee et 
al (2017) as described an association between cardiovascular disease and ARHL 75, supporting our 
results. 
As ARHL and hypertension are common and widespread disorders, especially in elderly subjects is 
not surprising that hypertension, as well as cardiovascular disease may influence ARHL, thus 
cardiologists should be add to the multidisciplinary team of professionals working to improve quality of 
life for these patients through a dynamic therapy process. 
The study of the association of demographic variables and clinical history of our subjects to ARHL 
has had various limitations, being the most impacting the incomplete questionnaires and the inability to 
obtain the audiometric data, usually due to cerumen occlusion. Also, smoking habits information is 
obtained as “current smoker”/“non smoker”, which makes us loose information about people who could 
have smoked but no longer do and this might influence the results.  
ARHL is thought to have an environmental and genetic component 13,15. It is estimated that 35-55% 
of auditory ageing has a genetic element 76.  
As previously stated, GRM7 SNP rs11928865 has been described as a risk factor for ARHL. In our 
sample, it was found a significant difference between genotypes for HL at 8000 Hz, however this results 
were lost when a multivariate logistic regression controlled by age was conducted. T allele in GRM7 is 
the most common in our sample of individuals with presbycusis. Genotypes A/T and T/T present 
respectively, 1.93 and 2.08 times higher hearing loss risk compared to A/A genotype, even though it is 
not statistically significant.  
Luo et al (2013) did a cluster analysis to group audiogram patterns and only found an association 
between GRM7 SNP rs11928865 and subjects with “sloping “and “abrupt loss” audiogram phenotype 
patterns in which anatomical function pathology was observed in the hair cells and in the spiral ganglion 
nerve cells 29. Similarly, studies conducted in European descendent (Non-Finnish and white American) 
population have described an association between GRM7 SNP rs11928865 and ARHL 28,30. The major 
difference between our study and the previous is sample size, which might justify the differences is 
statistical significance. Friedman et al (2009) have used human temporal bone specimens to localize 
mGluR7, which was detect by immunohistochemistry in the inner and outer hair cells and Hensens’ 
cells of the organ of Corti, in spiral ligament and the spiral ganglion neurons. From this study they 
hypothesize that an unidentified causative allele of GRM7 alters synaptic autoregulation of glutamate in 
the synaptic cleft of the sensory cells of the inner hair cells and the auditory neurons, leading to higher 
levels of glutamate, with subsequent neurotoxic effects and sensory cell death, thus leading to ARHL 
28.  
Oxidative stress is thought to contribute to the age process and consequently to ARHL. NAT2 is 
responsible for the detoxification of exogenic substrates and are vital to the oxidative balance. NAT2 is 
an isoenzyme highly polymorphic. Some of these polymorphisms may result in slow or rapid 
acetylators, having been both linked to diseases, such as cancer 31. In our sample, rapid acetylators have 
the lowest hearing loss and slow acetylators have the highest hearing loss, although no statistically 
significant differences were found. Nevertheless, it was observed a difference in the haplotypes at 250 
Hz, namely between NAT2*5B/NAT2*5B and NAT2*4/NAT2*6A, being the first the better listener 
and the 6A the worst listener. No other differences were found associating HL and NAT2 haplotypes. 
NAT2*6 and NAT2*5 lead to decreased protein expression and NAT2*5 leads to the greatest reduction 
in acetylation 31,77.  
Previous studies have identified NAT2*6A as a susceptibility genotype for ARHL, however these 
studies only focused on genotyping by real-time PCR 4 31 or 5 78 of the slow acetylator causing 
genotypes, therefore the differences in our results may be due to the higher number of SNPs evaluated, 
allowing to distinguish more haplotypes. 
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The haplogroups of mtDNA are a result of the evolution and migration of the modern human, 
presenting continental specific distribution, thus they are a product of adaptation to the environment. 
The ancestral-susceptibility model supports that some mtDNA haplogroups may confer certain disease 
susceptibility, as well as the penetrance of the clinical phenotype, with the change of environment and 
lifestyle in modern time. As the mtDNA haplogroups are characterized by distinct sets of variants, it is 
possible that certain mtDNA haplogroups can affect respiratory chain functions and may further perturb 
the crosstalk signalling 79,80. In our sample, it was possible to identify 15 haplogroups (H, HV, I, J K, L, 
M, N, R, T, U, V, W, X and Y), from which it is possible to distinguish 11 European haplogroups (H, 
HV, I, J, K, R, T, U, V, W, and X), the typically African L haplogroup and 3 Asian haplogroups (M, N 
and Y) 80. This high mixture of haplogroups in the Portuguese population might result from the historical 
expansionism and colonialism that might of allowed the mixture of people from different genetic 
backgrounds. 
The haplogroups with the highest HL is haplogroup X and with the lowest HL is haplogroup N. The 
most common haplogroup in our sample is haplogroup H, with a 34.1215.30 mean HL, which is 
agreement with the observed in the European population 80. In our sample, no haplogroup was identified 
as susceptible to ARHL. This is not in concordance with the literature, as Manwaring et al (2007) found 
an association between ARHL and haplogroups U and K 81 and Mostafa et al (2014) described a relation 
between haplogroup U and ARHL in a Egyptian and Italian cohort 82.  
These results suggest that the impact of other variables, such as environment, lifestyle and stochastic 
element, may have prevailed over the genetic factor, weakening the relation between GRM7, NAT2, 
mtDNA and ARHL. It also increases the relevance of identifying the various determinants of ARHL, 
leading to more targeted prevention programs. 
Nowadays it is possible to assay thousands of genetic variants in many individuals with high 
throughput techniques, accelerating the identification of susceptibility genes. The existence of 
reproducible quantitative traits of the disease is fundamental to these advances and ARHL benefits from 
this, has it can be evaluated by pure-tone and speech thresholds and supra-threshold hearing measures 
30.  
The use of only threshold data for a genetic analysis of ARHL can suffer a reduction in power due 
to genetic heterogeneity 30. Therefore, the use of only one test for the auditory assessment of the ARHL 
cohort is one of the limitations of this study, as different tests could have evaluated different aspects of 
the auditory system. Moreover, comparison of prevalence estimates from different studies is very 
difficult even when applying the same definition of HL, due to the differences in demographic 
characteristics across cohorts, especially age.  
The MD and VM patients sample underwent a complete neuro-otological evaluation, clinical history 
questionnaire, cytokine production quantification and gene expression array, in an attempt to find 
response differences between these diseases. 
Our results have found that basal levels of IL-1RA are increased in patients with VM comparing to 
healthy controls. MD patients with low levels of cytokines have lower production of IL-1RA and MD 
patients with high levels of cytokines have higher production of all cytokines, when compared to VM 
and healthy controls. Therefore, these observations allow us to distinguish VM from MD. 
The genes in the IL-1 complex code for three cytokines: IL-1α, IL-1β and the IL-1RA. The severity 
of a given infection is influenced by the balance between the levels of IL-1β and that of IL-1RA. In 
healthy individuals, IL-1RA is readily detectable in plasma and IL-1β levels are usually undetectable 83. 
Interestingly, IL-1RA levels were found to be much higher elevated in patients with MD and VM 
regardless of the levels of IL-1β. Since TLR10 is an anti-inflammatory pattern-recognition receptor able 
to up-regulate IL-1RA 84, and the TLR10 allelic variant rs11096955 has been associated with faster 
hearing loss progression in bilateral MD 85 , the activation of TLR10 could explain the increased levels 
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of IL-1RA found in patients with MD. Moreover, individuals bearing the TLR10 variant rs11096957 
displayed increased levels of IL-1β, TNF-α and IL-6 upon ligation of TLR2 84. Likewise, it has been 
described that there is an increase of IL-1RA in patients during episodes of migraine with and without 
aura 86.  
There is a much higher prevalence of allergy amongst MD patients than in healthy people. As there 
is a high overlap of symptoms between MD and VM, we investigated if the response to allergens 
(Aspergillus and Penicillium) might allow to distinguish these pathologies.  
Our results demonstrated that allergenic extracts from Aspergillus and Penicillium induce a 
proinflammatory immune response involving TNF-α and IL-6. This response is also more intense in 
VM than MD. Previous studies have established a relationship between mold extracts and 
proinflammatory cytokines in autoimmune inner ear disease (AIED) 87, demonstrating that when PBMC 
from patients with AIED were exposed to mold, it resulted in an up-regulation of IL-1β mRNA 
expression, and enhanced IL-6 and IL-1β secretion, suggesting that mold acts as a PAMP in a subset of 
these patients. Since most of our patients did not have a comorbid autoimmune disease, the elevation 
TNF-α and IL-6 observed in patients with MD after exposure of PBMC to Penicillium and Aspergilus 
cannot be explained by another autoimmune condition. Furthermore, it is well established that mold 
can cause respiratory symptoms and may worsen the course of bronchial asthma, which could lead 
to increase secretion of TNF-α, IL-6, IFN-γ or IL-1β 88,89.  
We found the CD28 signaling in T Helper cells and PI3K signaling in B Lymphocytes canonical 
pathways were inhibited in non-stimulated PBMC of MD patients with -levels of cytokines when 
compared to PBMC from VM patients. CD28 is a co-receptor of TCR-CD3 complex and provides a co-
stimulatory signal for T-cell activation. Naïve T-cell priming depends on the interaction between CD28, 
CD80 and CD86, inducing subsequently the production of IL-2 and clonal expansion for effective 
immune response. In naïve T-cells, CD28 co-stimulation increases cell cycle entry and facilitates the 
activation of anti-apoptotic program. Also, CD28 co-stimulation enhances the acquisition of T-helper 
cell-1 and 2 phenotypes 90,91. Phosphoinositide 3-kinases (PI3K) regulate numerous biological processes, 
such as cell growth, differentiation, survival, proliferation, migration and metabolism. B-cell 
development is facilitated by class I and III PI3K, through its defined stages, resulting in at least three 
distinct lineages of mature B-lymphocytes. In B-cells, PI3K is activated within seconds of antigen-
receptor triggering 92. Also, PI3K has been associated to the promotion of hair cell survival via its 
downstream targets  93 
On the other hand, iCOS-iCOSL signaling in T-helper cells and dendritic cell maturation canonical 
pathways are activated in non-stimulated PBMC of MD patients with -levels of cytokines when 
compared to PBMC from VM patients. Icos is stimulated by T-cell activation and is very low expressed 
on naïve T-cells. ICos-mediated signal contributes mainly to the regulation of activated T-cells and 
effector T-cell functions. The potency of ICos is enhanced following ICos ligation by ICosL (inducible 
T-cell co-stimulator ligand), which increases the production of cytokines. ICos-mediated signaling 
mainly generates Th1 and Th2 responses 94,95. Dendritic cell maturation leads to the upregulation of 
MHC class II and co-stimulatory molecules at the cell surface, CCR7-dependent migration to lymph 
nodes and promotes the release of cytokines that promote the differentiation of naïve T-cells, as well as 
other immune cells. Depending on the nature of the stimuli they sense, dendritic cells can produce 
distinct cytokines, such as IL-12, IL-15, IL-6 and TNF, triggering the differentiation of different types 
of effector T cells, allowing the adaptation of T-cell polarization to the specific nature of the threat 96. 
Taking into account the role of each of the pathways, differently expressed in non-stimulated PBMC 
of MD patients with -levels of cytokines and PBMC from VM patients, in T-cell differentiation, 
activation and regulation and B-cell development, we can predict that T-cell activation and B-cell 
development is reduced in MD when compared to VM. Considering the role of PI3K in hair cell survival, 
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after gentamicin conditioning 93 and the role of CD28 in the anti-apoptotic program, as they are down 
regulated in MD, it is possible that these pathways may lead to a higher cell death in MD and have a 
role in SNHL in MD. These results suggest that CD28 signaling in T-cells and PI3K signalling in B-
cells pathways might have a natural underexpression and, iCOS-iCOSL signaling in T-helper cells and 
dendritic cell maturation pathways an overexpression in MD patients with -level of cytokines. 
The differences seen in the extracellular levels of IL-6 and TNF-α between VM patients and MD 
patients with -levels of cytokines (figure 4.7), may be explained by the activated state of the dendritic 
cell maturation pathway in MD, as maturated dendritic cells can produce TNF and IL-6, which allows 
a response of T-cells to the stimuli. TNF has also been linked to corticosteroids responsiveness in 
immune-mediated SNHL 97. Therefore, this suggests that MD might be more immune mediated than 
allergic. 
Even though there are no statistically significant differences in these pathways, when comparing the 
gene expression profile of stimulated PBMC from MD against PBMC from VM patients, some of the 
key genes involved in them are significantly differently expressed (table 4.14 and table 4.15). TCR is 
activated by stimulation with Aspergillus, the pro-inflammatory, IL-2, CD3 and CD28 are activated by 
stimulation with Aspergillus and Penicillium, suggesting a T-cell activation and production of IL-2 is 
provoked by these stimuli. The absence of significance for the pathways may be due to the consideration 
of all MD patients and not only MD patients with -levels of cytokines for the comparison. 
The stimulation with Aspergillus and Penicillium cause the activation and inhibition of various genes. 
A comparison of these genes was conducted between MD patients and VM patients. 
Rictor is a regulatory component of the mammalian target of rapamycin complex 2 (mTORC2). Smrz 
et al (2014) demonstrated that rictor can function as a negative regulator in signalling events responsible 
for FcεRI- mediated mast cell degranulation independently of mTOR and by implication mTORC2, 
regulating critical events such as calcium mobilization and cytoskeletal rearrangement 98. As this gene 
is inhibited in MD when compared to VM, when stimulation with Aspergillus occurs, it suggests that a 
more intense allergic event takes place in VM patients, due to the release of histamine through mast cell 
degranulation99. 
X-box-binding protein 1 (XBP1) and Transcription factor 1 (E2F1) are seen activated in MD patients 
when compared to VM and stimulated with Aspergillus. XBP1 has a central role in regulating the 
expression of pro-inflammatory cytokines in macrophages, is essential for the development and survival 
of dendritic cells, and it is a major regulator of UPR, mediating adaptation to endoplasmic reticulum  
(ER) stress 100,101. ER stress is involved in various diseases, namely sensorineural hearing loss. 
Moreover, XBP1 mRNA splicing is implicated in the induction of autophagy in auditory cells 101. 
Transcription factor 1 (E2F1) is necessary to the regulation of the apoptosis process of DC and T cells 
and also supresses DC maturation 102. E2F1 also plays a role in stria vascularis, spiral ganglion apoptosis 
and progressive HL, in people with mtDNA A1555G mutation 103. Therefore, the study of XBP1 and 
E2F1 could be interesting in MD patients, to evaluate if they could have a role in NSHL in these patients.  
Prolactin (PRL), Hepatocyte growth factor (HGF), transcription factor STAT1, interferon type 2 
(IFNA2), toll-like receptor (TLR) 3 and interferon regulatory factor 3 (IRF3) are seen activated in MD 
patients when compared to VM and stimulated with Penicilium. 
PRL stimulates the humoral and cellular immune responses, accelerating the breakdown of immune 
tolerance by promoting the survival, maturation and activation of autoreactive B and T cells, dendritic 
cells and macrophages. Elevated serum levels of PRL have been reported in several autoimmune 
diseases, such as rheumatoid arthritis and systemic lupus erythematosus 104. 
HGF has a role in DC pathway decision: immune tolerance (triggering IL-10-dependent mechanism) 
or immunity 105. On the other hand, HGF signaling has a role in stria vascularis development and lack 
of HGF signaling in the inner ear leads to profound hearing loss in the mouse 106.  
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STAT1 is a transcription factor predominately involved in the signal transduction by either type I, 
type II, or type III IFNs. Furthermore, STAT1 regulates Th1 cell-specific cytokine production and 
controls the proliferation and apoptosis of immune cells. STAT1 mutations lead to STAT1 
hyperactivation and defective nuclear dephosphorylation, turning the individuals prone to fungal 
infections. This mutation leads to chronic mucocutaneous candidiasis, associated with exaggerated IFN-
γ signaling, which inhibits IL-17 transcription. These patients with increased IFN-γ signaling are also at 
risk for autoimmune disease. Systemic lupus erythematosus has also been associated to gain of function 
mutations in STAT1 107. The increase of activity of this gene in MD patients explains the increase of 
IFNA2 activity. 
TLR3 and TLR4 recognize fungal PAMPs 87. TLR3 and TLR4 recruit TRIF to trigger activation of 
TAK1, which activates TANK-binding kinase 1 (TBK1) and IkB kinase ε (IKKe), leading to the 
activation of IRF3 and induction of IFN-I expression. In the case of TLR4, another adaptor called TRAM 
is required to recruit TRIF for IRF3 activation. TRIF recruitment can also activate NFkB and MAPK 
through RIP1 or TAK1. Nuclear factor-kB (NFkB) activation is conserved among all TLR receptors, as 
well as the induction of pro-inflammatory cytokines such as TNFα and IL-1β. However, the ability to 
trigger IRF3 activation, and consequently IFN-I expression, is restricted to TLR4 and the nucleic acid 
sensing TLRs (TLR3, 7, 8, and 9) 96. 
Prostaglandin E receptor subtypes EP4 (PTGER4) and Trim24 are seen inhibited in MD patients 
when compared to VM and stimulated with Penicillium. 
Prostaglandin E1 has been used as a corticosteroid treatment for SNHL. PTGER4 mediates the 
physiological actions of prostaglandin E1 and E2. PTGER4 is coupled to G-protein stimulation, and 
mediates increases in cyclic adenosine monophosphate (cAMP) that activate protein kinase A (PKA). 
A study, demonstrates the involvement of PTGER4 in the regulation if VEGF synthesis in the inner ear 
(spiral ganglion neurons, the cochlear sensory epithelium, spiral ganglion, spiral ligament, and stria 
vascularis). PTGER4-mediated VEGF synthesis in the cochlea may be associated to protection against 
noise 108. 
Trim24 proteins are involved in gene regulation and cytokine signaling. Deletions in Trim24 do not 
lead to explicit autoimmune phenotype, however it is essential for Th2 cell-mediated airway allergy and 
Th2-dependent expulsion of intestinal helminthes 109. 
The state of the above genes in MD after stimulation by Penicillium suggests an autoimmune 
involvement and a higher reaction to mold. Contrastingly, the inhibition of Trim24 may suggest a higher 
allergic response in VM. Considering the role of HGF in HL and PTGER in the protection against HL, 
HGF activation and PTGER4 inhibition may be indicative of a link to SNHL in MD patients. 
Interferon-γ (IFNG), Interferon-α, tumor necrosis factor (TNF), IL-2, NFkB, myc, TLR4, IL-1A and 
HIF1A are seen activated in MD patients when compared to VM and stimulated with Aspergillus or 
Penicillium. On the other hand growth factor independent factor 1 (GFI1), CD3 and CD28 are seen 
inhibited under the same conditions. 
NFkB is essential to the regulation of apoptosis by controlling the expression of various anti-
apoptotic factors 90. Two potential regulatory variants in the NFKB1 gene (rs3774937 and rs4648011) 
were associated with a faster hearing loss progression in patients with unilateral SNHL. Steroids are 
potent blockers of NFkB pathway, which may explain the observed response to systemic steroids in 
patients with sudden SNHL or MD 110. It has been shown that TNFα induces a stronger activation of 
NFkB in the presence of IFN-γ 111. Therefore, the TNF activated state explains the increase in 
extracellular TNFα levels, which leads to a consequent activation of NFkB, after stimulation with mold. 
Myc is dominant over the hypoxia-inducible factor 1α (HIF1α) in regulating differentiation of naïve 
T cells into TEFF cells. HIF1α is vital in the metabolic switch to aerobic glycolysis that influences the 
balance of Th17/TREG in favour of Th17 cells. T cells with constitutively elevated HIF1α display 
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sustained increase of aerobic glycolysis and constitutively maintain effector function, reviling the 
essential role of HIF1α 112. 
GFI1A has an important role in controlling natural TREG development by regulating IL-2 production 
from convectional T-cells 113. Wallis et al (2003) found that knock-out of GFI1 in mice leads to defects 
that are consistent with inner ear anomalies, as they are ataxic, deaf and have head tilting behaviour, 
being both the vestibular and cochlear hair cells affected. Gfi1 is expressed in the developing nervous 
system, is necessary for inner ear hair cell differentiation and its loss causes programmed cell death114. 
The state of these genes in the response to both molds reveal the involvement of an higher immune 
response and support the higher SNHL prevalence in MD patients than in VM patients. 
Various pathways are altered in response to Aspergillus and Penicillium in VM patients comparing 
to healthy controls. 
IL-8 is a key chemoattractant and activator of neutrophils. The most prominent producer of IL-8 in 
vitro is the monocyte population of PBMC. There are numerous non-specific cytokines, ligands and 
metabolic stimulants that induce IL-8 gene expression in monocytes and PBMC, however it has been 
described that in sites of TNFα accumulation there is a high production of IL-8 115. The IL-8 signaling 
pathway is seen inhibited when stimulated with Aspergilus and activated when stimulated with 
Penicillium. This may be explained by the higher production of TNFα in PBMC stimulated with 
Penicillium (figure 4.6). 
TLR are characterized pattern recognition receptors (PRRs), able to detect a variety of pathogen-
associated molecular patterns (PAMPs), such as lipids, proteins, lipoproteins, and nucleic acids. TLR 
activation can induce inflammatory cytokines (TNF-α, IL-6), co-stimulatory molecules, type I and type 
II and interferon and chemokines. All TLRs except TLR3 utilize MyD88 for the production of 
inflammatory cytokines or type I IFNs (TLR7, TLR8, and TLR9). TLR activates NFkB and MAPKs for 
regulation of pro- and anti-inflammatory cytokine production 116,117.  Toll-like Receptor Signaling and 
NFkB signalling pathways are inhibited in VM patients compared to healthy controls, however 
observing the level of extracellular cytokines obtained in our results it is possible to conclude that these 
pathways have been active. A possible explanation for this is that the response of VM patients was more 
intense and all the mRNA was converted into protein before the harvest of the cells and RNA extraction. 
Apoptosis plays a role in the shut-down of cellular as well as humoral immune responses. In the case 
of acute immune response, foreign antigen-specific T and B cells can expand several hundred-fold in 
numbers, which differenciate into effector cells, to overcome the pathogens by killing them, either 
directly or indirectly through cytokine-mediated activation of cells of the innate immune system. After 
the defeat of the pathogen, effector cells undergo programmed death, as they are no longer needed, 
restoring normal cellularity. Also, apoptosis of activated lymphocytes minimizes the collateral damage 
to healthy tissues that can be caused by the immune effector molecules (e.g. inflammatory cytokines, 
immune complexes, perforin-granzymes) 118. The inhibited state of the Death Receptor Signaling 
pathway in VM patients suggest that VM patients may take longer to activate t-cell apoptosis after 
stimulation with mold. 
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6. Conclusion and further directions 
This study has focused on inner ear disease and as allowed us to draw the following conclusions: 
1) Inner ear disorders are very complex and have many possible causes as well as comorbidities; 
2) Our results show that the Portuguese ARHL population has various types of comorbidities, such 
as cholesterol and diabetes. 
3) Regarding the genetic factors evaluated, GRM7 SNP rs11928865 A/A genotype and 
NAT2*4/NAT2*6A have the lowest HL. 
4) For our sample, mtDNA haplogroup showed no effect on HL. 
5) The combined results on the study of ARHL suggest that in our population environmental 
factors may have a higher input into ARHL than the genetic factors evaluated. 
6) VM patients can be distinguished from MD patients and healthy controls according to their IL-
1RA levels without stimulation. 
7) Aspergillus and Penicillium provoke an increase in IL-6 and TNF-α production in VM and MD, 
which although distinguishable from healthy controls, the levels of stimulation among the 
diseases is very similar. 
8) The microarray results unveiled the involvement of many genes and pathways in MD and VM, 
which suggest a higher allergic response in VM. 
9) The microarray data is supportive of the findings in the extracellular cytokine measurements. 
 
ARHL should be perceived as a disease of preventable nature as well as treatable. Therefore, further 
genetic screening should be conducted, for identification of functional variants that will allow impact 
assessment of genotype on phenotypic outcomes of interest. Also proteomics and microarrays may be 
used to detect predictors of disease susceptibility. This combined information can reveal new 
mechanisms involved in ARHL, hinting towards pharmaceutical targets and screening kits. 
The next steps, in the study of VM and MD, should be conducting longitudinal experiments in the 
same patients, to assess if the increase in the cytokines is persistent or fluctuating over time; try to further 
investigate the downstream effects of IL-6 and TNF-α to define candidate targets for therapy and to 
define additional cytokines in separated immune cell populations to figure out which cell types are 
driving the response to molds. 
The recognition of different subgroups of patients in MD is the first step to improve the selection of 
patients for genetic and immunological studies, therefore increasing the number of patients with MD 
type 4 in our sample would be advantageous in studies to further differentiate MD from VM, has it is 
the MD type with most overlapping symptoms.  
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8. Annexes 
 
A. WHO standardized hearing loss classification 
 
Table 8.1 – WHO standardized hearing loss classification 
WHO Classification Hearing loss (dB) Hearing Stage 
Normal <26 0 
Mild 26-40 1 
Moderate 41-60 2 
Severe 61-80 3 
Profound >80 4 
 
B. Diagnostic criteria for VM 
 
A. At least 5 episodes fulfilling criteria C and D. 
B. A current or past history of migraine with(out) aura. 
C. Vestibular symptoms of moderate or severe intensity, lasting between 5 minutes and 72 hours. 
D. At least 50% of episodes associated with at least 1 of the following 3 migrainous features: 
i. Headache with at least 2 of the following 4 characteristics: unilateral headache; pulsating 
quality; moderate to severe intensity; or aggravation by routine physical activity 
ii. Photophobia and phonophobia 
iii. Visual aura 
E. Not better accounted for by another ICHD-3β diagnosis or by another vestibular disorder. 
 
C. PCR protocols 
 
Table 8.2 - mtDNA PCR protocol. 
 Temperature (ºC) Time Number of cycles 
Initial denaturation 95 3’ 1 
Denaturation 95 15’’ 
35 Annealing 60 15’’ 
Extension 72 15’’ 
Final extension 72 1’ 1 
 
Table 8.3 - NAT2 PCR protocol 
 Temperature (ºC) Time Number of cycles 
Initial denaturation 95 3’ 1 
Denaturation 95 15’’ 
35 Annealing 61.6 15’’ 
Extension 72 1’’ 
Final extension 72 1’ 1 
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Table 8.4 - GRM7 real-time PCR protocol 
 Temperature (ºC) Time Number of cycles 
Pre-PCR 
60 30’’ 1 
50 2’ 1 
Initial denaturation 95 10’ 1 
Denaturation 95 15’’ 40 
Annealing 60 30’’ 40 
Extension 72 30’’ 40 
Post-PCR 60 30’’ 1 
    
 
Table 8.5 - qPCR protocol 
 Temperature (ºC) Time Number of cycles 
Pre-PCR 95 20’’ 1 
Denaturation 95 1’’ 40 
Annealing/Extension 60 20’’ 40 
 
D. Demographic Results 
 
Table 8.6 – Influence of demographics and clinical history on HL based on the WHO classification. 
 Normal (≤25 dB) HL (>25 dB) p-value 
Sex 
Feminine 77 151 (66.2%) 
0.716 
Masculine 36 78 (68.4%) 
Age 
mean±SD 68.65±7.96 78.37±8.53 <0.001* 
Cholesterol 
Yes 69 91 (56.9%) 
0.009* 
No 34 90 (72.6%) 
Hypertension 
Yes 54 127 (70.2%) 
0.022* 
No 48 62 (56.4%) 
Tinnitus 
Yes 74 119 (61.7%) 
0.520 
No 33 65 (66.3%) 
Diabetes 
Yes 21 58 (73.4%) 
0.124 
No 73 127 (63.5%) 
Smoking 
Yes 30 43 (58.9%) 
0.327 
No 77 147 (65.6%) 
Cardiovascular Disease 
Yes 17 69 (80.2%) 
0.003* 
No 77 126 (62.1%) 
Noise Exposure 
Yes 31 70 (69.3%) 
0.162 
No 77 119 (60.7%) 
Ototoxic Medication 
Yes 23 29 (55.8%) 
0.520 
No 68 108 (61.4%) 
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E. NAT2 haplotype 
 
Table 8.7 - Distribution of individuals according to NAT2 haplotype and associated mean HLSD 
Genotype Frequency (%) HLSD (dB) 
4/5U 70 (21.0) 37.0216.19 
4/5B 60 (18.0) 34.9217.01 
5B/5B 53 (15.9) 35.6616.64 
4/6A 49 (14.7) 30.4613.56 
6A/6A 24 (7.2) 31.5113.87 
4/4 19 (5.7) 31.9116.46 
4/5A 7 (2.1) 37.1421.19 
5A/5B 6 (1.8) 26.677.97 
4/5V 3 (0.9) 32.0815.02 
4/7B 3 (0.9) 32.9210.10 
5B/5C 3 (0.9) 30.0016.54 
6J/13A 3 (0.9) 31.6711.34 
12A/5B 2 (0.6) 44.387.96 
4/12C 2 (0.6) 27.500.00 
4/5G 2 (0.6) 34.3829.17 
5B/12A 2 (0.6) 29.384.42 
5B/5D 2 (0.6) 20.6311.49 
11A/5B 1 (0.3) 49.75NA 
12A/12C 1 (0.3) 21.25NA 
12B/12B 1 (0.3) 35.00NA 
13A/13A 1 (0.3) 38.35NA 
13A/14B 1 (0.3) 60.00NA 
4/12A 1 (0.3) 23.75NA 
4/12B 1 (0.3) 43.75NA 
4/13A 1 (0.3) 16.25NA 
4/14B 1 (0.3) 46.25NA 
4/5D 1 (0.3) 60.00NA 
4/5J 1 (0.3) 23.75NA 
4/5R 1 (0.3) 47.50NA 
5A/11A 1 (0.3) 31.25NA 
5B/13A 1 (0.3) 28.75NA 
5B/6A 1 (0.3) 52.50NA 
5D/5G 1 (0.3) 7.50NA 
5R/12A 1 (0.3) 27.50NA 
5U/6B 1 (0.3) 61.25NA 
6A/13A 1 (0.3) 15.636.19 
6A/6B 1 (0.3) 18.75NA 
6J/7B 1 (0.3) 31.25NA 
6N/6N 1 (0.3) 17.50NA 
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F. mtDNA haplotypes 
 
Table 8.8 - Distribution of individuals according to mtDNA haplogroup and associated mean HLSD. 
Haplogroup N (%) Mean HL SD (dB) 
H 172 (51.19) 34.1215.30 
U 35 (10.42) 31.8614.77 
HV 24 (7.14) 35.0514.97 
T 23 (6.85) 38.4219.13 
L 19 (5.65) 28.6211.92 
J 16 (4.76) 33.9114.84 
X 11 (3.27) 43.3016.04 
K 9 (2.68) 36.1120.89 
V 9 (2.68) 33.7522.83 
R 5 (1.49) 42.0018.15 
I 4 (1.19) 41.5628.82 
W 4 (1.19) 40.6310.92 
N 3 (0.89) 19.584.39 
M 1 (0.30) 23.75NA 
Y 1 (0.30) 43.75NA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
